NCT01840254

Brief Summary

The aim of this study is to test the hypothesis that addition of dexmedetomidine to fentanyl-based intravenous patient controlled analgesia (PCA) reduces requirement of fentanyl bolus and consequent postoperative nausea and vomiting in high-risk patients undergoing lumbar spine surgery.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
108

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Sep 2012

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

September 1, 2012

Completed
8 months until next milestone

First Submitted

Initial submission to the registry

April 17, 2013

Completed
8 days until next milestone

First Posted

Study publicly available on registry

April 25, 2013

Completed
4 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 1, 2013

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

September 1, 2013

Completed
Last Updated

February 7, 2014

Status Verified

February 1, 2014

Enrollment Period

1 year

First QC Date

April 17, 2013

Last Update Submit

February 5, 2014

Conditions

Keywords

PONVIV PCAdexmedetomidineFemalenon-smokinglumbar spine surgery

Outcome Measures

Primary Outcomes (1)

  • total dose and bolus administration of opioid

    After induction of anesthesia, peak velocity of carotid artery blood flow is measured by the pulsed wave Doppler signal obtained from the left common carotid artery. Respirophasic variation of the peak velocity is defined as the difference between the maximum and the minimum values of peak velocity divided by the mean of the two values during one respiratory cycle. Fluid responder is defined as a patient whose stroke volume index is increased ≥15% after volume expansion. The receiver operating characteristic curve analysis to discriminiate fludi responder is performed.

    an expected average of 48 hrs for requirements of total dose and number of bolus administration of PCA

Secondary Outcomes (1)

  • consequent postoperative nausea and vomiting

    an expected average of 48 hrs for assessing of the 11-points verbal numerical rating scales

Study Arms (2)

dexmedetomidine

EXPERIMENTAL

addition of dexmedetomidine to fentanyl-based intravenous patient controlled analgesia (PCA)

Drug: dexmedetomidine

normal saline

PLACEBO COMPARATOR

normal saline as a placebo

Drug: normal saline

Interventions

dexmedetomidine
normal saline

Eligibility Criteria

Age20 Years - 65 Years
Sexfemale
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • \. female, non-smoking patient who are 20-65 of age scheduled for elective lumbar spine surgery

You may not qualify if:

  • Bradycardia on EKG (45bpm)
  • Atrioventricular conduction disorder
  • Uncontrolled hypertension
  • angina history
  • obesity (BMI ≥ 30 kg/m2)
  • Preoperative administration of opioid
  • Preoperative administration of antiemetics
  • Gastrointestinal disorder history
  • Hepatic or renal disease
  • Pregnant 11. Foreigner

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Yonsei University College of Medicine

Seoul, Seoul, 120-752, South Korea

Location

Related Publications (1)

  • Song Y, Shim JK, Song JW, Kim EK, Kwak YL. Dexmedetomidine added to an opioid-based analgesic regimen for the prevention of postoperative nausea and vomiting in highly susceptible patients: A randomised controlled trial. Eur J Anaesthesiol. 2016 Feb;33(2):75-83. doi: 10.1097/EJA.0000000000000327.

MeSH Terms

Conditions

Postoperative Nausea and Vomiting

Interventions

DexmedetomidineSaline Solution

Condition Hierarchy (Ancestors)

Postoperative ComplicationsPathologic ProcessesPathological Conditions, Signs and SymptomsNauseaSigns and Symptoms, DigestiveSigns and SymptomsVomiting

Intervention Hierarchy (Ancestors)

ImidazolesAzolesHeterocyclic Compounds, 1-RingHeterocyclic CompoundsCrystalloid SolutionsIsotonic SolutionsSolutionsPharmaceutical Preparations

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, OUTCOMES ASSESSOR
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

April 17, 2013

First Posted

April 25, 2013

Study Start

September 1, 2012

Primary Completion

September 1, 2013

Study Completion

September 1, 2013

Last Updated

February 7, 2014

Record last verified: 2014-02

Locations